6932.TWO Mercury Biopharmaceutical Corporation
- Market cap
- TWD 2.20B
- P/E
- -
- P/B
- 11.61x
- ROE
- -30.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6932.TWO undervalued?
Graham numberThe Graham number of Mercury Biopharmaceutical Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mercury Biopharmaceutical Corporation fundamental analysis
No fundamental analysis for Mercury Biopharmaceutical Corporation yet.
Mercury Biopharmaceutical Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mercury Biopharmaceutical Corporation
Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulat…
Full company profileMercury Biopharmaceutical Corporation financial statements
Mercury Biopharmaceutical Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 2.68M | 1.03M | 4.96M | 0.00 |
| Gross Profit | - | 0.00 | 1.17M | 592K | 4.18M | 0.00 |
| Operating Income | -210K | -5.30M | -30.9M | -43.1M | -54.0M | -68.5M |
| EBITDA | -210K | -4.33M | -28.1M | -39.0M | -42.3M | -54.6M |
| Net Income | -210K | -5.31M | -31.3M | -43.8M | -50.6M | -67.2M |
| EPS | 0.00 | -0.02 | -0.08 | -0.11 | -0.12 | -0.16 |
| Balance Sheet | ||||||
| Total Assets | 97.0K | 13.4M | 230M | 438M | 353M | 278M |
| Total Liabilities | 306K | 2.93M | 49.6M | 49.7M | 62.9M | 58.7M |
| Shareholders' Equity | -209K | 10.5M | 180M | 388M | 290M | 220M |
| Cash & Short-term Investments | 86.0K | 2.56M | 141M | 329M | 68.0M | 53.2M |
| Total Debt | 300K | 2.01M | 43.4M | 42.3M | - | - |
| Cash Flow | ||||||
| Operating Cash Flow | -217K | -4.78M | -25.8M | -42.1M | -34.7M | -50.8M |
| Capital Expenditure | 0.00 | 7.51M | 68.7M | 13.6M | 11.1M | 7.30M |
| Free Cash Flow | -217K | -12.3M | -94.5M | -55.7M | -45.8M | -58.1M |
| Ratios | ||||||
| ROE | - | -50.8% | -17.3% | -11.3% | -17.4% | -30.6% |
| ROA | -216.5% | -39.7% | -13.6% | -10.0% | -14.3% | -24.2% |
| Net Profit Margin | - | - | -1,166.0% | -4,241.6% | -1,018.9% | - |
| Debt to Equity | - | 0.19x | 0.24x | 0.11x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mercury Biopharmaceutical Corporation dividends
Mercury Biopharmaceutical Corporation has not paid dividends in the last 7 fiscal years.
Who owns Mercury Biopharmaceutical Corporation
Ownership data of Mercury Biopharmaceutical Corporation is not available yet.
Mercury Biopharmaceutical Corporation company profile
- Company name
- Mercury Biopharmaceutical Corporation
- Ticker
- 6932.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- No. 653, Bannan Rd., New Taipei City, Taiwan, 235030
- Phone
- 886 2 8221 2020
- Website
- merdury.com
About Mercury Biopharmaceutical Corporation
Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.
Mercury Biopharmaceutical Corporation management
5- Mr. Yaoren LiangGM & Director
- Chun Chun ZhangVP of Administration & Accounting Supervisor
- Mr. Ruixing ChenLegal Director & Director
- Mr. Nanxiong ZhangChief Marketing Officer & Director
- Chaoyi ChenChief Research & Development Officer